Back to Search
Start Over
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
- Source :
- The Lancet Haematology; April 2021, Vol. 8 Issue: 4 pe267-e277, 11p
- Publication Year :
- 2021
-
Abstract
- R-MegaCHOEP was the first phase 3 study comparing high-dose chemotherapy plus rituximab followed by autologous haematopoietic stem-cell transplantation (HSCT) with conventional chemotherapy plus rituximab in first-line therapy for patients aged 60 years or younger with high-risk aggressive B-cell lymphoma. Little is known about the long-term outcomes of these patients. We aimed to evaluate the long-term efficacy and safety of conventional chemotherapy versus high-dose chemotherapy after 10 years of follow-up in the R-MegaCHOEP trial.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 8
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs55677098
- Full Text :
- https://doi.org/10.1016/S2352-3026(21)00022-3